Danaher Co. (NYSE:DHR) EVP Joakim Weidemanis Sells 22,433 Shares

Danaher Co. (NYSE:DHR) EVP Joakim Weidemanis sold 22,433 shares of the firm’s stock in a transaction on Thursday, April 25th. The stock was sold at an average price of $250.46, for a total transaction of $5,618,569.18. Following the completion of the sale, the executive vice president now owns 90,412 shares of the company’s stock, valued at $22,644,589.52. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Danaher Price Performance

DHR opened at $246.45 on Friday. The company has a market capitalization of $182.54 billion, a price-to-earnings ratio of 41.77, a PEG ratio of 4.19 and a beta of 0.83. The company has a quick ratio of 1.37, a current ratio of 1.85 and a debt-to-equity ratio of 0.31. The firm has a 50-day moving average price of $248.87 and a 200-day moving average price of $231.08. Danaher Co. has a twelve month low of $182.09 and a twelve month high of $259.00.

Danaher (NYSE:DHR) last posted its earnings results on Tuesday, April 23rd. The conglomerate reported $1.92 earnings per share for the quarter, topping the consensus estimate of $1.72 by $0.20. The firm had revenue of $5.80 billion during the quarter, compared to the consensus estimate of $5.62 billion. Danaher had a net margin of 16.78% and a return on equity of 11.43%. The company’s revenue was down 2.6% on a year-over-year basis. During the same quarter last year, the company earned $2.36 earnings per share. Equities analysts expect that Danaher Co. will post 7.64 EPS for the current year.

Danaher Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, April 26th. Stockholders of record on Thursday, March 28th were paid a $0.27 dividend. This is an increase from Danaher’s previous quarterly dividend of $0.24. The ex-dividend date of this dividend was Wednesday, March 27th. This represents a $1.08 annualized dividend and a dividend yield of 0.44%. Danaher’s dividend payout ratio (DPR) is presently 18.31%.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on DHR shares. Bank of America raised their price objective on shares of Danaher from $258.00 to $270.00 and gave the company a “neutral” rating in a research note on Wednesday. TD Cowen raised their price objective on shares of Danaher from $280.00 to $290.00 and gave the company a “buy” rating in a research note on Wednesday. Citigroup raised their price objective on shares of Danaher from $280.00 to $290.00 and gave the company a “buy” rating in a research note on Wednesday. HSBC raised shares of Danaher from a “hold” rating to a “buy” rating and raised their price objective for the company from $250.00 to $280.00 in a research note on Wednesday, April 17th. Finally, Barclays raised their price objective on shares of Danaher from $260.00 to $270.00 and gave the company an “equal weight” rating in a research note on Wednesday. Six analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. Based on data from MarketBeat.com, Danaher has an average rating of “Moderate Buy” and an average target price of $270.00.

Hedge Funds Weigh In On Danaher

Hedge funds have recently bought and sold shares of the company. Tsfg LLC grew its stake in Danaher by 733.3% during the first quarter. Tsfg LLC now owns 100 shares of the conglomerate’s stock valued at $25,000 after acquiring an additional 88 shares in the last quarter. Cape Investment Advisory Inc. purchased a new position in Danaher during the fourth quarter valued at approximately $25,000. BKM Wealth Management LLC purchased a new position in Danaher during the fourth quarter valued at approximately $27,000. Redmont Wealth Advisors LLC purchased a new position in Danaher during the first quarter valued at approximately $30,000. Finally, Wetzel Investment Advisors Inc. purchased a new position in Danaher during the fourth quarter valued at approximately $29,000. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.